Gesynta Pharma AB

Gesynta Pharma AB, a clinical-stage pharmaceutical company, has appointed Eva Johnsson as its new Chief Medical Officer and Vice President of Clinical Development. Eva Johnsson, who has extensive experience in clinical drug development and medical affairs, previously worked at Grünenthal and AstraZeneca R&D. She is also an associate professor at the University of Gothenburg. Gesynta Pharma is preparing a Phase II clinical trial for vipoglanstat, a new treatment for endometriosis, a chronic inflammatory disease affecting women. The trial will involve around 190 patients across Europe. Patric Stenberg, CEO of Gesynta Pharma, expressed confidence in Eva's ability to enhance the company's clinical development capabilities. As Eva Johnsson takes on her new role, Charlotte Edenius will transition to a strategic position as VP R&D Strategy. Gesynta Pharma focuses on developing treatments targeting the enzyme mPGES-1, with vipoglanstat being their lead compound. The company is also preparing GS-073 for clinical trials for chronic inflammatory pain. Gesynta Pharma's shareholders include Hadean Ventures, Industrifonden, and Innovestor Life Science.

Gesynta Pharma AB has secured SEK 304 million in a Series B financing round led by Innovestor Life Science. The funds will support a Phase II clinical trial of vipoglanstat, a non-hormonal drug candidate for treating endometriosis, a chronic inflammatory disease affecting 190 million women worldwide. The trial aims to address the inadequacies of current treatments, which often have significant side effects. The financing attracted new European and U.S. investors and existing shareholders. The trial will enroll about 190 patients to evaluate the drug's efficacy and safety. Gesynta Pharma's research focuses on targeting mPGES-1, an enzyme involved in inflammatory processes. The company also plans to develop another drug candidate, GS-073, for chronic inflammatory pain.